Abstract
This phase II trial studies the effects of trastuzumab deruxtecan in treating patients with
HER2 positive osteosarcoma that is newly diagnosed or has come back (recurrent). Trastuzumab
deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called
deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers
deruxtecan to kill them.
